Derrington Taletha Mae, Bernstein Judith, Belanoff Candice, Cabral Howard J, Babakhanlou-Chase Hermik, Diop Hafsatou, Evans Stephen R, Kotelchuck Milton
Education Division, Center for Education and Human Services, SRI International, 333 Ravenswood Avenue, BS179, Menlo Park, CA, 94025, USA.
Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA.
Matern Child Health J. 2015 Oct;19(10):2168-78. doi: 10.1007/s10995-015-1730-1.
Substance use disorder (SUD) in women of reproductive age is associated with adverse health consequences for both women and their offspring. US states need a feasible population-based, case-identification tool to generate better approximations of SUD prevalence, treatment use, and treatment outcomes among women. This article presents the development of the Explicit Mention Substance Abuse Need for Treatment in Women (EMSANT-W), a gender-tailored tool based upon existing International Classification of Diseases, 9th Edition, Clinical Modification diagnostic code-based groupers that can be applied to hospital administrative data. Gender-tailoring entailed the addition of codes related to infants, pregnancy, and prescription drug abuse, as well as the creation of inclusion/exclusion rules based on other conditions present in the diagnostic record. Among 1,728,027 women and associated infants who accessed hospital care from January 1, 2002 to December 31, 2008 in Massachusetts, EMSANT-W identified 103,059 women with probable SUD. EMSANT-W identified 4,116 women who were not identified by the widely used Clinical Classifications Software for Mental Health and Substance Abuse (CCS-MHSA) and did not capture 853 women identified by CCS-MHSA. Content and approach innovations in EMSANT-W address potential limitations of the Clinical Classifications Software, and create a methodologically sound, gender-tailored and feasible population-based tool for identifying women of reproductive age in need of further evaluation for SUD treatment. Rapid changes in health care service infrastructure, delivery systems and policies require tools such as the EMSANT-W that provide more precise identification methods for sub-populations and can serve as the foundation for analyses of treatment use and outcomes.
育龄女性的物质使用障碍(SUD)会给女性及其后代带来不良健康后果。美国各州需要一种可行的基于人群的病例识别工具,以更好地估算女性中SUD的患病率、治疗利用率和治疗结果。本文介绍了女性明确提及物质滥用治疗需求(EMSANT-W)工具的开发过程,这是一种基于现有《国际疾病分类》第九版临床修订版诊断编码分组器的针对性别设计的工具,可应用于医院管理数据。针对性别设计包括添加与婴儿、怀孕和处方药滥用相关的编码,以及根据诊断记录中存在的其他情况制定纳入/排除规则。在2002年1月1日至2008年12月31日期间在马萨诸塞州接受医院护理的1,728,027名女性及相关婴儿中,EMSANT-W识别出103,059名可能患有SUD的女性。EMSANT-W识别出4,116名未被广泛使用的心理健康和物质滥用临床分类软件(CCS-MHSA)识别的女性,且未涵盖CCS-MHSA识别出的853名女性。EMSANT-W在内容和方法上的创新解决了临床分类软件的潜在局限性,并创建了一种方法合理、针对性别设计且可行的基于人群的工具,用于识别需要进一步评估SUD治疗的育龄女性。医疗服务基础设施、提供系统和政策的快速变化需要诸如EMSANT-W这样的工具,该工具可为亚人群提供更精确的识别方法,并可作为分析治疗使用情况和结果的基础。